The Spring 2020 Group Meeting will be virtual (April 28-30) More Here
Our clinical trials are enrolling patients during the pandemic More Here
Read the latest issue of our News from ECOG-ACRIN blog
Read our Advocacy Blog on screening and surveillance
Read the Q4 2020 issue of the TMIST Study Updates Newsletter
Question about COVID19? Send an email
Read about the rationale for the currently enrolling EA5181 study. The primary objective is to evaluate whether there is an improvement in overall survival in the group of patients with stage 3 non-small cell lung cancer that receives concurrent and consolidative therapy with MEDI4736 (durvalumab) immunotherapy. February 17, 2021. The Oncologist
Results from E1412, a signal-finding randomized phase II trial, show that the addition of lenalidomide to R-CHOP improves outcomes in patients with newly diagnosed diffuse large B-cell lymphoma. Epub February 8, 2021. Journal of Clinical Oncology
Efficacy of capivasertib in treating mutated metastatic tumors, as shown in Arm Y of the NCI-MATCH trial. January 18, 2021. Physician’s Weekly
Capivasertib may be helpful against tumors with rare AKT mutation, as shown in the NCI-MATCH trial’s Arm Y. January 11, 2021. Reuters Health Information via Medscape
Now Enrolling: EA3191 for head and neck cancer patients. January 08, 2021. More Here
The results of NCI-MATCH Arm Y show that the drug capivasertib had a clinically significant objective response rate of 28.6% in 35 patients with AKT1 E17K-mutated metastatic tumors. December 30, 2020. JAMA Oncology
A new publication prospectively assesses the effects of chemoradiation on quality of life, especially swallowing and voice function, in patients with locally advanced head and neck cancer in the E2399 trial. December 22, 2020. Cancers of the Head and Neck
Video: Roisin M. Connolly, MD, lead investigator for study E2112, discusses the trial results. Entinostat addition fails to improve aromatase inhibitor-resistant breast cancer outcomes. December 14, 2020. Medicine Matters Oncology
The new RSClinTM tool integrates clinical-pathological and genomic risk to guide adjuvant chemotherapy in node-negative breast cancer and provides more individualized information than clinical-pathological or genomic data alone, according to Joseph Sparano, MD, and colleagues. December 11, 2020. Journal of Clinical Oncology
Better Together: Clinical and Genomic Data to Inform Shared Decision Making. An editorial accompanying RSClinTM validation analysis. December 11, 2020. Journal of Clinical Oncology
New data from the CHAARTED trial (E3805) shows that reliance on prostate-specific antigen (PSA) alone is an inadequate strategy to monitor patients undergoing treatment for metastatic hormone-sensitive prostate cancer. December 3, 2020. European Urology Oncology
First-ever phase III clinical trial opens for patients with advanced, inoperable anal cancer. November 16, 2020. Read Press Release
In a survey of 204 sites in the NCI Community Oncology Research Program (NCORP), only 40% had a process to identify and document cancer caregivers. November 2, 2020 (epub ahead of print). Cancer
View our YouTube channel for these and other videos:
Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.
The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.
We look forward to sharing our research and partnering with you, as we reshape the future of patient care.
Robert L. Comis, MD